An inflammation-related prognostic model risk score predicts the prognosis of Clear cell renal cell carcinoma
Background: Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant tumors of the urinary system, and the prognosis of patients with advanced stage is really poor. Existing evidence suggests that inflammation and inflammation-related genes play complex roles in different tumors, but their role in ccRCC has rarely been studied as a primary research object. Methods: we used The Cancer Genome Atlas (TCGA) database to established a prognostic model risk score for ccRCC and
... mation-related genes and verified its predictive effect on the prognosis of ccRCC.Result: We screened 10 inflammatory differentially expressed genes (DEGs) with independent prognostic value for ccRCC and constructed a prognostic model risk score: (-0.0153×APLNR) + (-0.0073×BTG2) +0. 0225×CSF1+ (-0.0107×CX3CL1) +0. 1888×GABBR1+0. 1528×HAS2+0. 0088×ICAM1+0. 3952×P2RY2+ (-0.0442×SPHK1) +0. 0006×TIMP1. The survival analysis showed that ccRCC with a higher risk score implies shorter survival and worse prognosis. Then we used univariate and multivariate Cox regression analysis and Receiver Operating Characteristic (ROC) curve to confirm that the risk score has a good and stable independent prognostic value. and performed an internal validation of the risk score. Gene set enrichment analysis (GSEA) showed that high risk groups were involved in many pathways related to the occurrence and development of tumors. we also found that the expression levels of immune checkpoints including PD-1, CTLA-4, LAG3, TIGIT in ccRCC in the high risk group were significantly higher than those in the low risk group, and the ESITIMATE tool showed that the high risk group had lower tumor purity and greater heterogeneity. Conclusion: Our study initially revealed the role of inflammatory genes in ccRCC, and provided a prognostic model risk score that could predict the prognosis of ccRCC well, and may provide more information for future research and treatment of ccRCC.